AMNOG service capability

We help you identify and realize the full price potential of your drug

Germany is Europe’s largest pharmaceutical market, making AMNOG one of the most influential pricing and market access processes in Europe. At the same time, the environment for patent-protected medicines is becoming more challenging. Regulatory changes, increasing cost pressure, higher internal price expectations – including those driven by MFN policies – and growing evidence requirements are raising the stakes for pharmaceutical and biotech companies. The introduction of EU HTA adds another dimension, requiring companies to align European evidence planning with national market access and pricing requirements.

AMNOG provides the governing framework for the benefit assessment of new medicines by the G-BA and the subsequent negotiation of the reimbursement price negotiation with the GKV-SV. Navigating this complex process requires a holistic pricing and market access strategy. An integrated P&MA strategy connects medical innovation, health economic value, and negotiation logic from the outset – long before a company formally submits a dossier. Each element should ultimately strengthen the AMNOG price negotiation and support the best possible price outcome.

As an experienced AMNOG strategy consulting partner in Germany, we support pharmaceutical companies across the entire process - combining in-depth German market access expertise with pricing strategy consulting and providing hands-on price negotiation support from launch through arbitration.